CN107744577A - 一种治疗胃黏膜损伤的中药组合物 - Google Patents
一种治疗胃黏膜损伤的中药组合物 Download PDFInfo
- Publication number
- CN107744577A CN107744577A CN201611255710.4A CN201611255710A CN107744577A CN 107744577 A CN107744577 A CN 107744577A CN 201611255710 A CN201611255710 A CN 201611255710A CN 107744577 A CN107744577 A CN 107744577A
- Authority
- CN
- China
- Prior art keywords
- parts
- chinese medicine
- medicine composition
- cockroach
- american
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 58
- 239000000203 mixture Substances 0.000 title claims abstract description 49
- 230000009854 mucosal lesion Effects 0.000 title claims abstract description 36
- 239000000284 extract Substances 0.000 claims abstract description 24
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims abstract description 20
- 229960001138 acetylsalicylic acid Drugs 0.000 claims abstract description 20
- 244000001632 Acorus gramineus Species 0.000 claims abstract description 14
- 235000013073 Acorus gramineus Nutrition 0.000 claims abstract description 14
- 241000132012 Atractylodes Species 0.000 claims abstract description 14
- 244000197580 Poria cocos Species 0.000 claims abstract description 14
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 14
- 240000004980 Rheum officinale Species 0.000 claims abstract description 14
- 235000008081 Rheum officinale Nutrition 0.000 claims abstract description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 230000006378 damage Effects 0.000 claims description 9
- 210000002784 stomach Anatomy 0.000 claims description 9
- 241000238675 Periplaneta americana Species 0.000 claims description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- 239000012141 concentrate Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 238000001035 drying Methods 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 6
- 230000002829 reductive effect Effects 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 238000001914 filtration Methods 0.000 claims description 4
- 239000000463 material Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 230000006837 decompression Effects 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 239000004519 grease Substances 0.000 claims description 3
- 238000010992 reflux Methods 0.000 claims description 3
- 238000005057 refrigeration Methods 0.000 claims description 3
- 238000007873 sieving Methods 0.000 claims description 3
- 230000000295 complement effect Effects 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 22
- 230000009471 action Effects 0.000 abstract description 3
- 210000001156 gastric mucosa Anatomy 0.000 description 13
- 102100040247 Tumor necrosis factor Human genes 0.000 description 10
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 8
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 8
- 102000015271 Intercellular Adhesion Molecule-1 Human genes 0.000 description 7
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 230000002401 inhibitory effect Effects 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 5
- 230000001681 protective effect Effects 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 208000007882 Gastritis Diseases 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102000057297 Pepsin A Human genes 0.000 description 2
- 108090000284 Pepsin A Proteins 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 210000004907 gland Anatomy 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 229940111202 pepsin Drugs 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 240000000233 Melia azedarach Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- JMLGXYWHNOKLBE-HOTXNYTESA-A alicaforsen sodium Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=NC=NC(N)=C3N=C2)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C(N=C(N)C=C2)=O)COP([O-])(=S)O[C@@H]2[C@H](O[C@H](C2)N2C3=C(C(NC(N)=N3)=O)N=C2)CO)[C@@H](OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=C(C(NC(N)=N3)=O)N=C2)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(NC(=O)C(C)=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C(N=C(N)C=C2)=O)OP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)O)C1 JMLGXYWHNOKLBE-HOTXNYTESA-A 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000006502 antiplatelets effects Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940085350 aspirin 75 mg Drugs 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 208000023652 chronic gastritis Diseases 0.000 description 1
- 235000019504 cigarettes Nutrition 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000011532 immunohistochemical staining Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/56—Materials from animals other than mammals
- A61K35/63—Arthropods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/708—Rheum (rhubarb)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/752—Citrus, e.g. lime, orange or lemon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8969—Polygonatum (Solomon's seal)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9064—Amomum, e.g. round cardamom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Insects & Arthropods (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种治疗胃黏膜损伤的中药组合物,所述组合物由以下成分按重量份组成:美洲大蠊提取物5份、陈皮6份、石菖蒲3份、大黄2份、茯苓3份、玉竹3份、白术6份、砂仁6份;将该中药组合物用于预防和治疗胃黏膜损伤有显著的效果,特别是针对阿司匹林所致的胃黏膜损伤,其作用效果较单独使用美洲大蠊提取物的效果显著,说明本发明所述的中药组合物能有效减轻阿司匹林所致胃黏膜损伤。
Description
技术领域
本发明属于医药领域,特别涉及一种治疗胃黏膜损伤的中药组合物。
背景技术
胃黏膜损伤是导致胃溃疡及急慢性胃炎的主要病理生理学环节,其损伤的产生是由于胃黏膜攻击性因素及保护/防御性因素失去平衡所造成的。胃黏膜防御因子包括黏液-碳酸氢盐屏障、胃黏膜上皮细胞屏障、胃黏膜血流量等;引起胃黏膜损伤的攻击因子包括吸烟、胃酸、胃蛋白酶、幽门螺旋杆菌、非甾体抗炎药、应激反应和心理因素等。
阿司匹林具有显著的镇痛、抗炎和抗血小板作用,在临床上的应用上十分广泛,其最常见的不良反应就是胃黏膜损伤。近年来针对中药对胃粘膜保护作用的研究和应用也不断增加,研究表明中药对胃粘膜的保护作用主要通过抑制胃酸、胃蛋白酶的分泌,强化胃粘膜-粘液屏障作用,改善胃粘膜血液循环,抑制杀灭幽门螺杆菌,诱导胃粘膜内源性保护因子的合成和释放,增强胃黏膜细胞保护作用等途径来实现。中药具有药性缓和、不易产生耐药性、适合长期服用等优点,能有效的中和或降低各种化学药物产生的副作用,增加其治疗作用。
美洲大蠊,具有收敛止血,消肿生肌的效用,其提取物能促进肉芽组织生长,帮助机体受损组织迅速修复,抗炎及增强机体免疫功能的作用,对于外伤创面有显著的修复效用,而陈皮、石菖蒲、大黄、茯苓、玉竹、白术、砂仁等中药在胃黏膜损伤方面具有一定的效用。关于美洲大蠊与陈皮、石菖蒲、大黄、茯苓、玉竹、白术、砂仁联合用于预防和治疗阿司匹林所致胃黏膜损伤药物中的应用目前尚未见研究报道。
发明内容
本发明的目的在于提供一种治疗胃黏膜损伤的中药组合物,所述组合物在预防和治疗阿司匹林所致小鼠胃黏膜损伤药物具有显著的效果。
为实现上述发明目的,本发明提供如下的技术方案:
本发明所述的一种治疗胃黏膜损伤的中药组合物,该组合物由以下成分按重量份组成:美洲大蠊提取物3~12份、陈皮4~10份、石菖蒲2~6份、大黄1~4份、茯苓2~6份、玉竹2~6份、白术4~10份、砂仁4~10份;
优选的,所述组合物的由以下成分按重量份组成:美洲大蠊提取物5份、陈皮6份、石菖蒲3份、大黄2份、茯苓3份、玉竹3份、白术6份、砂仁6份。
所述中药组合物的制备方法是通过以下方案实现的:
①称取美洲大蠊,粉碎,加入原药材重量的10~12倍的70~90%的乙醇在70~95℃下回流提取3次,时间为1~3小时,过滤,滤液减压浓缩后,在60~65℃测其比重为1.10~1.20,浓缩液中加入浓缩液重量的10~12倍的纯水,70~80℃下搅拌20分钟,冷藏静置,上层油脂用滤纸吸去,将下层液过滤后再经减压浓缩、干燥、粉碎,即得美洲大蠊提取物;
②称取陈皮、石菖蒲、大黄、茯苓、玉竹、白术、砂仁,粉碎,过筛80目备用;共煎煮3次,前两次每次加水4~6倍量,煎煮2~4小时,第三次煎煮时,加水1~3倍量,煎煮1~2小时,将三次煎煮的煎液合并后过滤,收集滤液备用;
③将步骤①所得的美洲大蠊提取物与步骤②所得的煎煮混合液进行混合,搅拌均匀,再经减压浓缩、干燥、粉碎,即得中药组合物。
本发明的另一个目的为提供一种中药组合物在制备治疗和预防胃黏膜损伤的药物中的应用。
所述的中药组合物还可以加上药学上可接受的辅料或辅助性成分。
所述的胃黏膜损伤为阿司匹林所致的胃黏膜损伤。
本发明通过美洲大蠊与各种中药制备组合物,将其用于预防和治疗阿司匹林所致胃黏膜损伤药物中,通过实验验证得到,所述中药组合物对阿司匹林所致的胃黏膜损伤有抑制作用,其抑制率达到62.34%~80.25%,该组合物的作用效果较单独使用美洲大蠊提取物的效果显著。
具体实施方式
以下结合实施例的具体实施方式对本发明的内容作进一步的详细说明。
实施例1中药组合物的制备方法
①称取美洲大蠊,粉碎,加入原药材重量的12倍的80%的乙醇在85℃下回流提取3次,时间为1小时,过滤,滤液减压浓缩后,在60~65℃测其比重为1.10~1.20,浓缩液中加入浓缩液重量的12倍的纯水,80℃下搅拌20分钟,冷藏静置,上层油脂用滤纸吸去,将下层液过滤后再经减压浓缩、干燥、粉碎,即得美洲大蠊提取物;
②称取陈皮、石菖蒲、大黄、茯苓、玉竹、白术、砂仁,粉碎,过筛80目备用;共煎煮3次,前两次每次加水5倍量,煎煮3小时,第三次煎煮时,加水2倍量,煎煮1小时,将三次煎煮的煎液合并后过滤,收集滤液备用;
③将步骤①所得的美洲大蠊提取物与步骤②所得的煎煮混合液进行混合,搅拌均匀,再经减压浓缩、干燥、粉碎,即得中药组合物。
实施例2
所述组合物的由以下成分按重量份组成:美洲大蠊提取物50g、陈皮60g、石菖蒲30g、大黄20g、茯苓30g、玉竹30g、白术60g、砂仁60g。
将处方量的各味中药材按照实施例1所述的方法制备,即得本发明所述的中药组合物。
实施例3
所述组合物的由以下成分按重量份组成:美洲大蠊提取物30g、陈皮40g、石菖蒲20g、大黄10g、茯苓20g、玉竹20g、白术40g、砂仁40g。
将处方量的各味中药材按照实施例1所述的方法制备,即得本发明所述的中药组合物。
实施例4
所述组合物的由以下成分按重量份组成:美洲大蠊提取物120g、陈皮100g、石菖蒲60g、大黄40g、茯苓60g、玉竹60g、白术100g、砂仁100g。
将处方量的各味中药材按照实施例1所述的方法制备,即得本发明所述的中药组合物。
以上实施例2~实施例4任意一项所述的组合物可以加上药学上常用的辅料或辅助性成分,制成胶囊剂、片剂、缓释制剂、液体制剂等口服制剂。
以下将通过实验例对本发明所述的药物在治疗阿司匹林所致胃黏膜损伤药物中的应用做进一步的说明。
实验例1中药组合物在制备治疗和预防胃黏膜损伤药物中的应用
1实验材料
1.1实验动物
SD大鼠,雄性,体重200~250g,由达硕生物科技有限公司提供。
1.2实验药物
阿司匹林片(哈药集团制药总厂);
美洲大蠊提取物:按照实施例1所述的方法制备得到;
实施例2~实施例4所述的中药组合物。
2实验方法
2.1实验分组
SD大鼠60只,随机等分为6组:正常对照组、模型对照组、美洲大蠊提取物组、实施例2组、实施例3组、实施例4组。正常对照组、模型组按2ml/100g灌服生理盐水,各给药组按1.5g/kg每日灌服相应药物一次,连续给药7天。
2.2大鼠阿司匹林诱发胃黏膜损伤模型
SD大鼠除正常对照组外,模型组和各给药组均给予阿司匹林75mg/kg,连续给药7天,末次给药前24小时禁食,前12小时禁水。最后一次给药1h后处死动物。
2.3观察指标和方法
2.3.1胃粘膜损伤指数(UI)的测定
动物处死后,取出胃,沿大鼠侧弯剪开,将胃粘膜组织取出用冰生理盐水冲洗后,胃粘膜面向上展平于生理盐水纱布上。在解剖显微镜(×10)下仔细计数胃腺部点线状糜烂及出血点数目,按Guth标准评定损伤指数:损伤长度≤1mm计1分,>1~2mm计2分,>2~3mm计3分,>3~4mm计4分,>4mm计5分,宽度>2mm时,分数乘以2,最后以全胃病灶分数总和计算Guth评分。
2.3.2免疫组化染色胞间粘附分子-1(ICAM-1)和肿瘤坏死因子(TNF-α)的表达
胃腺部损伤组织常规ABC法染色ICAM和TNF-α,结果采用MAS图像分析系统,每张切片选5个视野,测出每平方毫米组织切片的阳性细胞数。
3实验结果
3.1药物对阿司匹林所致胃黏膜损伤大鼠胃黏膜损伤指数的影响
通过观察发现,正常对照组胃大鼠胃粘膜光泽红润,无损伤,胃粘膜表面上皮的隐窝细胞形态正常,腺体结构完整。模型对照组阿司匹林灌胃后胃粘膜表面上皮细胞广泛脱落,粘膜内有出血,腺体受损。
表1药物对阿司匹林所致胃黏膜损伤大鼠胃黏膜损伤指数的影响(n=10,)
注:各给药组与模型组比较,**为P<0.01;模型组与正常组比较,○○为P<0.01;各实施例组与美洲大蠊提取物组比较,△为P<0.05,△△为P<0.01。
由表1可知,阿司匹林可诱发大鼠胃黏膜损伤,而各给药组可不同程度的减轻胃黏膜损伤,对胃黏膜损伤的抑制率可达到62.34%~80.25%,其中各实施例组对阿司匹林所致胃黏膜损伤的抑制效果较单独使用美洲大蠊提取物的效果佳,以实施例2组的抑制效果最好,抑制率为80.25%。
3.2药物对胞间粘附因子(ICAM)和肿瘤坏死因子(TNF-α)表达的影响
表2药物对阿司匹林所致胃黏膜损伤大鼠胃组织ICAM-1和TNF-α
表达阳性细胞数的影响(n=10,)
注:各给药组与模型组比较,**为P<0.01;模型组与正常组比较,○○为P<0.01;各实施例组与美洲大蠊提取物组比较,△为P<0.05,△△为P<0.01。
由表2可知,正常对照组ICAM-1和TNF-α阳性表达的细胞数很少,而模型对照组ICAM-1和TNF-α阳性表达显著,与正常对照组存在显著性差异。各给药组与模型对照组相比,其减少ICAM-1和TNF-α阳性表达细胞数的效果显著,各实施例组的效果较单独使用美洲大蠊提取物的效果显著。
通过上述实验例可以看出,本发明所述的中药组合物对阿司匹林所致的胃黏膜损伤有抑制作用,同时可显著减少ICAM-1和TNF-α阳性表达的细胞数,所述中药组合物的作用效果较单独使用美洲大蠊提取物的效果显著;各实施例组中以实施例2所述的组合物作用效果最好,抑制率可达到80.25%,能有效的改善阿司匹林所致胃黏膜损伤。
本发明的有益效果
本发明通过制备美洲大蠊与陈皮、石菖蒲、大黄、茯苓、玉竹、白术、砂仁组成的中药组合物,通过实验研究发现该中药组合物用于预防和治疗胃黏膜损伤有显著的效果,特别是针对阿司匹林所致的胃黏膜损伤,其作用效果较单独使用美洲大蠊提取物的效果显著。说明本发明所述的中药组合物对胃黏膜损伤具有一定的保护作用。
Claims (5)
1.一种治疗胃黏膜损伤的中药组合物,其特征在于,所述组合物的由以下成分按重量份组成:美洲大蠊提取物3~12份、陈皮4~10份、石菖蒲2~6份、大黄1~4份、茯苓2~6份、玉竹2~6份、白术4~10份、砂仁4~10份。
2.根据权利要求1所述的一种治疗胃黏膜损伤的中药组合物,其特征在于,所述组合物的由以下成分按重量份组成:美洲大蠊提取物5份、陈皮6份、石菖蒲3份、大黄2份、茯苓3份、玉竹3份、白术6份、砂仁6份。
3.根据权利要求1所述的中药组合物,其特征在于,所述中药组合物的制备方法如下:
①称取美洲大蠊,粉碎,加入原药材重量的10~12倍的70~90%的乙醇在70~95℃下回流提取3次,时间为1~3小时,过滤,滤液减压浓缩后,在60~65℃测其比重为1.10~1.20,浓缩液中加入浓缩液重量的10~12倍的纯水,70~80℃下搅拌20分钟,冷藏静置,上层油脂用滤纸吸去,将下层液过滤后再经减压浓缩、干燥、粉碎,即得美洲大蠊提取物;
②称取陈皮、石菖蒲、大黄、茯苓、玉竹、白术、砂仁,粉碎,过筛80目备用;共煎煮3次,前两次每次加水4~6倍量,煎煮2~4小时,第三次煎煮时,加水1~3倍量,煎煮1~2小时,将三次煎煮的煎液合并后过滤,收集滤液备用;
③将步骤①所得的美洲大蠊提取物与步骤②所得的煎煮混合液进行混合,搅拌均匀,再经减压浓缩、干燥、粉碎,即得中药组合物。
4.权利要求1~3任意一项所述的中药组合物在制备治疗和预防胃黏膜损伤的药物中的应用;
其中,所述的中药组合物还可以加上药学上可接受的辅料或辅助性成分。
5.根据权利要求4所述的应用,其特征在于,所述的胃黏膜损伤为阿司匹林所致的胃黏膜损伤。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611255710.4A CN107744577B (zh) | 2016-12-30 | 2016-12-30 | 一种治疗胃黏膜损伤的中药组合物 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201611255710.4A CN107744577B (zh) | 2016-12-30 | 2016-12-30 | 一种治疗胃黏膜损伤的中药组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107744577A true CN107744577A (zh) | 2018-03-02 |
CN107744577B CN107744577B (zh) | 2020-12-22 |
Family
ID=61254644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201611255710.4A Active CN107744577B (zh) | 2016-12-30 | 2016-12-30 | 一种治疗胃黏膜损伤的中药组合物 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107744577B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112057476A (zh) * | 2020-09-15 | 2020-12-11 | 四川好医生攀西药业有限责任公司 | 一种组合物及其在醒酒解宿醉护胃上的应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101837023A (zh) * | 2010-05-25 | 2010-09-22 | 耿福能 | 一种治疗胃炎和消化性溃疡的美洲大蠊药物组合物及其制备方法 |
CN101837095A (zh) * | 2010-05-25 | 2010-09-22 | 耿福能 | 一种治疗胃炎和消化性溃疡的美洲大蠊药物组合物及其制备方法 |
CN105535780A (zh) * | 2015-12-25 | 2016-05-04 | 百花医药集团股份有限公司 | 一种香砂六君制剂的制作方法 |
-
2016
- 2016-12-30 CN CN201611255710.4A patent/CN107744577B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101837023A (zh) * | 2010-05-25 | 2010-09-22 | 耿福能 | 一种治疗胃炎和消化性溃疡的美洲大蠊药物组合物及其制备方法 |
CN101837095A (zh) * | 2010-05-25 | 2010-09-22 | 耿福能 | 一种治疗胃炎和消化性溃疡的美洲大蠊药物组合物及其制备方法 |
CN105535780A (zh) * | 2015-12-25 | 2016-05-04 | 百花医药集团股份有限公司 | 一种香砂六君制剂的制作方法 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112057476A (zh) * | 2020-09-15 | 2020-12-11 | 四川好医生攀西药业有限责任公司 | 一种组合物及其在醒酒解宿醉护胃上的应用 |
Also Published As
Publication number | Publication date |
---|---|
CN107744577B (zh) | 2020-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Yu et al. | Citri Reticulatae Pericarpium (Chenpi): Botany, ethnopharmacology, phytochemistry, and pharmacology of a frequently used traditional Chinese medicine | |
US8163312B2 (en) | Herbal formulation for prevention and treatment of diabetes and associated complications | |
US7390514B2 (en) | Herbal composition for treatment and maintenance of hormone dependent conditions, osteoporosis, circulatory conditions, and for use as an immunostimulant | |
CN101664482B (zh) | 治疗脚气和皮肤瘙痒的外用药及其制备方法 | |
CN104940258B (zh) | 一种具有保护胃黏膜功能的中药提取物组合 | |
CN107753538A (zh) | 一种蜚蠊与三七的组合物及其应用 | |
CN107744577A (zh) | 一种治疗胃黏膜损伤的中药组合物 | |
CN101152223B (zh) | 杨树叶酚类提取物在制备治疗心律失常的药物中的应用 | |
CN103784934B (zh) | 一种防治急性心肌梗死的药物组合物及其应用 | |
CN108835615A (zh) | 一种用于辅助降血压的组合物 | |
CN102139006A (zh) | 一种治疗肝损伤的复方胡黄连组合物及其制备方法和用途 | |
CN112755168B (zh) | 一种治疗幽门螺旋杆菌引起的慢性胃炎的中药制剂及其制备方法和应用 | |
CN103690832A (zh) | 一种治疗病毒性心肌炎的中药组合物 | |
CN103656226A (zh) | 一种治疗干燥综合征复方药 | |
CN106334171A (zh) | 一种用于修复肝损伤的中药制剂及制备方法 | |
CN102552711B (zh) | 治疗高血压的中药组合物 | |
CN110279744A (zh) | 一种保肝护肝复方中药制剂及其制备方法 | |
CN103920023A (zh) | 一种治疗高血压的中药 | |
CN102309550A (zh) | 一种防治暑湿疾病的中药气雾剂及其制备方法 | |
CN103055122A (zh) | 预防冠脉支架植入术后再狭窄的药物及其制备方法 | |
CN102824446B (zh) | 一种具有抗疲劳作用的药物组合物及其制备方法与应用 | |
CN107213343A (zh) | 一种含白及的口腔溃疡中药药膏及其制备方法 | |
CN108143944A (zh) | 一种治疗伤风的中药组合物 | |
CN103816224A (zh) | 治疗急慢性鼻炎的中药制剂及其生产方法的改进 | |
CN106334050A (zh) | 防治痰瘀阻窍型肺癌脑转移中药制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |